Jenny L Wiley Selected Research

Cannabinoid Receptor Agonists

1/2018	Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.
5/2015	Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
12/2013	Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
6/2012	1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.
1/2011	Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jenny L Wiley Research Topics

Disease

24	Hypothermia 01/2021 - 10/2002
18	Catalepsy 01/2021 - 06/2003
6	Pain (Aches) 01/2020 - 07/2004
4	Substance-Related Disorders (Drug Abuse) 10/2014 - 12/2009
4	Schizophrenia (Dementia Praecox) 12/2008 - 02/2003
3	Hyperalgesia 01/2020 - 02/2007
3	Pica (Geophagia) 01/2019 - 01/2017
2	Inflammation (Inflammations) 01/2020 - 12/2005
2	Cardiotoxicity 01/2019 - 01/2018
2	Mental Disorders (Mental Disorder) 01/2018 - 01/2008
2	Tobacco Use Disorder (Nicotine Dependence) 11/2017 - 09/2010
2	Neuralgia (Stump Neuralgia) 12/2015 - 05/2015
2	Tremor (Tremors) 08/2015 - 04/2014
2	Weight Loss (Weight Reduction) 04/2014 - 07/2004
2	Multiple Sclerosis 04/2008 - 01/2006
1	Lung Injury 08/2022
1	Chronic Pain 01/2020
1	Edema (Dropsy) 01/2020
1	Dehydration (Water Stress) 01/2019
1	Seizures (Absence Seizure) 01/2019
1	Poisoning 01/2018
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2017
1	Coma (Comas) 01/2017
1	Nervous System Diseases (Neurological Disorders) 01/2017
1	Delirium 01/2017
1	Tachycardia (Tachyarrhythmias) 11/2014
1	Hyperthermia 11/2014
1	Psychotic Disorders (Schizoaffective Disorder) 11/2014
1	Marijuana Abuse (Cannabis Abuse) 03/2013
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/2013
1	Marijuana Use 03/2013
1	Obesity 11/2012
1	Ataxia (Dyssynergia) 10/2012
1	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 05/2009
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2009
1	Smith-Magenis Syndrome 08/2008

Drug/Important Bio-Agent (IBA)

21	CannabinoidsIBA 01/2020 - 10/2002
15	Dronabinol (THC)FDA LinkGeneric 01/2021 - 06/2003
8	Pharmaceutical PreparationsIBA 01/2018 - 12/2005
5	Cannabinoid Receptor AgonistsIBA 01/2018 - 01/2011
4	RimonabantIBA 01/2020 - 12/2013
3	CannabidiolIBA 01/2020 - 04/2008
3	5F-CUMYL-PICAIBA 01/2019 - 01/2017
3	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2017 - 05/2015
3	EndocannabinoidsIBA 12/2009 - 07/2004
3	Clozapine (Clozaril)FDA LinkGeneric 02/2009 - 09/2008
3	Haloperidol (Haldol)FDA LinkGeneric 02/2009 - 09/2008
3	Antipsychotic Agents (Antipsychotics)IBA 12/2008 - 06/2003
2	Freund's AdjuvantIBA 01/2020 - 02/2007
2	Medical MarijuanaIBA 01/2020 - 01/2018
2	methyl 2- (1- (4- fluorobenzyl)- 1H- indazole- 3- carboxamido)- 3- methylbutanoateIBA 01/2019 - 01/2018
2	indoleIBA 01/2019 - 01/2017
2	Nicotine FDA Link 11/2017 - 03/2017
2	Dopamine (Intropin)FDA LinkGeneric 11/2017 - 12/2008
2	AerosolsIBA 03/2017 - 01/2017
2	N- (1- (aminocarbonyl)- 2- methylpropyl)- 1- (cyclohexylmethyl)- 1H- indazole- 3- carboxamideIBA 01/2017 - 09/2015
2	Illicit Drugs (Recreational Drugs)IBA 07/2013 - 03/2013
2	SulfonamidesIBA 11/2012 - 01/2011
2	anandamide (arachidonylethanolamide)IBA 01/2006 - 03/2005
2	N-Methylaspartate (NMDA)IBA 08/2003 - 02/2003
1	Acetates (Acetic Acid Esters)FDA Link 08/2022
1	Vitamin E FDA LinkGeneric 08/2022
1	EG-018IBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	CytokinesIBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	InterferonsIBA 01/2020
1	InterleukinsIBA 01/2020
1	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 01/2020
1	IndazolesIBA 01/2019
1	Cyanides (Isocyanides)IBA 01/2019
1	AmidesIBA 01/2019
1	anatabineIBA 11/2017
1	myosmineIBA 11/2017
1	Cocaine (Cocaine HCl)IBA 01/2017
1	LigandsIBA 01/2017
1	CarrageenanIBA 12/2015
1	N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- pentyl- 1H- indazole- 3- carboxamideIBA 09/2015
1	MJN110IBA 05/2015
1	JZL 184IBA 05/2015
1	piperidineIBA 05/2015
1	PiperazineIBA 05/2015
1	Phenol (Carbolic Acid)FDA Link 05/2015
1	3- (2- hydroxy- 4- (1,1- dimethylheptyl)phenyl)- 4- (3- hydroxypropyl)cyclohexanolIBA 05/2015
1	SaltsIBA 11/2014
1	XLR-11IBA 12/2013
1	(1- pentyl- 1H- indol- 3- yl)(2,2,3,3- tetramethylcyclopropyl)methanoneIBA 12/2013
1	pyrazoleIBA 11/2012
1	Synthetic CathinoneIBA 10/2012
1	(6aR,10aR)- 3- (1- methansulfonylamino- 4- hexyn- 6- yl)6a,7,10,10a- tetrahydro- 6,6,9- trimethyl- 6H- dibenzo(b,d)pyranIBA 01/2011
1	Bupropion (Wellbutrin)FDA LinkGeneric 09/2010
1	hydroxybupropionIBA 09/2010
1	salvinorin AIBA 06/2010
1	EnzymesIBA 12/2009
1	JZL195IBA 12/2009
1	tyrosyl-DNA phosphodiesteraseIBA 05/2009

Therapy/Procedure

3	Analgesia 01/2017 - 01/2006
2	Therapeutics 01/2020 - 01/2017
1	Induced Hypothermia 03/2017